[go: up one dir, main page]

WO1996035705A1 - Inhibition, au moyen d'une invasion de brins oligomeres, de l'activation par transcription induite par un facteur de transcription - Google Patents

Inhibition, au moyen d'une invasion de brins oligomeres, de l'activation par transcription induite par un facteur de transcription Download PDF

Info

Publication number
WO1996035705A1
WO1996035705A1 PCT/US1996/006673 US9606673W WO9635705A1 WO 1996035705 A1 WO1996035705 A1 WO 1996035705A1 US 9606673 W US9606673 W US 9606673W WO 9635705 A1 WO9635705 A1 WO 9635705A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligomer
site
transcription factor
modified
double
Prior art date
Application number
PCT/US1996/006673
Other languages
English (en)
Inventor
Timothy A. Vickers
Original Assignee
Isis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals, Inc. filed Critical Isis Pharmaceuticals, Inc.
Priority to AU58565/96A priority Critical patent/AU5856596A/en
Publication of WO1996035705A1 publication Critical patent/WO1996035705A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Definitions

  • This invention is directed to compositions and methods for inhibition of transcriptional activation by the use of oligomers that include naturally-occurring bases or other nucleic acid-binding moieties covalently bound to a polyamide backbone.
  • This invention relates to the design and synthesis of oligomers that form triple-stranded structures with double-stranded nucleic acids. It also relates to the use of such oligomers in effecting strand displacement in double-stranded nucleic acids.
  • mRNA messenger RNA
  • tRNAs transfer RNAs
  • RNA polymerase Initiation of transcription requires specific recognition of a promoter DNA sequence by an RNA polymerase. In eukaryotic cells, this recognition may be preceded by binding of a protein molecule known as a transcription factor or transactivator to the promoter in a sequence- specific manner. Proteins which bind to the promoter to effect inhibition of RNA polyraerase are known as repressors. In certain instances, transcription factors may function as both activators and repressors.
  • Transcription factors are one of the largest and most diverse classes of DNA-binding proteins that regulate gene expression by binding to specific sites on DNA. By interfering with binding of transcription factors to DNA, inhibition of transcriptional activation and gene expression is effected and subsequently protein synthesis directed by that gene is also inhibited. Oligomer compositions that interfere with transcription factor binding to DNA and inhibit transcriptional activation may serve as diagnostic reagents for determining the involvement of a transcription factor in a given disease state. Such oligomer compositions may also serve as therapeutic agents for the treatment of disease conditions arising as a result of transcription factor-mediated transcriptional activation leading to production of a protein which may be associated with a disease state.
  • triplex formation involves binding of an oligonucleotide to duplex DNA and is based on Watson-Crick hydrogen bonding and Hoogsteen or reversed Hoogsteen hydrogen bonding between duplex base pairs and oligonucleotide bases. It has been shown that the oligodeoxynucleotides may be pyrimidine-rich or purine-rich, or may be mixed purine-pyrimidine oligodeoxynucleotides.
  • Hogan and Paul disclose triplex forming oligonucleotides that inhibit cell proliferation. These oligonucleotides are capable of binding to the major groove of a DNA duplex forming a colinear triplex with the promoter region of the erb B2/neu gene, thereby interfering directly with the regulatory molecules that bind to the major groove.
  • Taniguchi U.S. Patent 5,157,115 discloses DNA and RNA compositions that bind competitively to those regions of the IL-2 or IL-2ot genes which correspond to the binding sites of their respective transcription factors. Inhibition of binding of a transcription factor to its binding site on a gene results in inhibition of gene expression.
  • Holcenberg and Wu describe compositions and methods for controlling gene expression by competitively binding the transcription factor to a double- stranded "decoy" oligonucleotide and competitively inhibiting the binding of the transcription factor to a transcriptional control element of the gene.
  • oligomers for modulating the activity of a gene are provided. These oligomers are specifically hybridizable with DNA, and bind to double-stranded DNA (dsDNA) with high affinity.
  • the oligomers may inhibit transcription factor binding to dsDNA and subsequent transcriptional activation by forming triple helices with dsDNA wherein a first oligomer binds to one strand of dsDNA forming a duplex and in doing so displaces the other strand of dsDNA, a second oligomer then binds to the resulting duplex thereby forming a triple helix.
  • Strand displacement and formation of a triple helix results in inhibition of binding of a transcription factor to the dsDNA.
  • inhibition of binding of a transcription factor to DNA results in inhibition of transcriptional activation.
  • the oligomers of the invention are believed to bind to DNA with Watson-Crick hydrogen bonding and Hoogsteen hydrogen bonding. It is further believed that reverse Hoogsteen hydrogen bonding may also be utilized by the oligomers in binding to dsDNA.
  • the oligomers comprise a plurality of monomer units attached to a polyamide backbone, which oligomers are referred to as peptide nucleic acids or PNAs, and are specifically hybridizable with DNA.
  • PNA oligomers may form triple helices with dsDNA, e . g. (PNA) 2 /DNA.
  • substantially all monomer units of PNA oligomers are pyrimidine bases.
  • the present invention is also directed to methods for inhibiting transcriptional activation of a gene by inhibiting the binding of a transcription factor to dsDNA with an oligomer in accordance with the foregoing considerations.
  • aspects of the invention are directed to methods for diagnostics and therapeutics of animals believed to have a disease state arising due to transcriptional activation of DNA mediated by a transcription factor.
  • Such methods comprise contacting the animal, or cells, tissues or a bodily fluid from the animal, with an oligomer in accordance with the invention, in order to inhibit binding of the particular transcription factor responsible for initiating the disease state to its binding site on DNA.
  • This inhibition of transcription factor binding to DNA inhibits gene expression thereby inhibiting production of the protein that causes and/or maintains the disease state.
  • the oligomers of the invention are also useful as research reagents.
  • Figure 1 is a diagram depicting the sequence of the region surrounding the NFKB site and the homopyrimidine strand invasion site of the IL-2R ⁇ 5' untranslated region.
  • the NFKB site is shown in boldface, and the homopyrimidine site is underlined.
  • the binding orientations of the PNA oligomers, ISIS 9151 and ISIS 8129, are shown beneath the homopyrimidine strand invasion site.
  • Figure 2 is an autoradiogram which depicts the effect of ISIS 9151 on NFKB binding in vi tro .
  • the open arrow indicates the position of the strand invaded DNA duplex, while the solid arrow indicates the position of the DNA duplex bound to p50.
  • Figure 3 is an autoradiogram depicting the inhibition of in vi tro transcriptional activation by ISIS 9151.
  • the 870-nucleotide transcript was visualized by electrophoresis on a denaturing gel.
  • Figure 4 is a bar graph which depicts inhibition of NFcB-induced transactivation of pGL- ⁇ B in HL 2/3 cells.
  • the luciferase activity shown has been normalized to that exhibited by the uninduced control (first bar of each set) .
  • oligomers that modulate transcription factor-dependent transcriptional activation are provided. These oligomers are useful as diagnostics for determination of the transcription factor responsible for a disease condition. These oligomers are also useful as therapeutic agents for the treatment of disease conditions arising as a result of aberrant or abnormal gene expression which is mediated by a particular transcription factor.
  • oligomers such as oligonucleotides
  • oligomers can be used to control gene expression by antisense, decoy or triplex mechanisms.
  • gene expression is inhibited by oligomer binding to a specific sequence of double-stranded DNA (dsDNA) , thereby forming a triple helix that inhibits transcription of the target gene.
  • dsDNA double-stranded DNA
  • Preferred PNA oligomers according to the present invention have the formula:
  • n is at least 5, i.e. a pentamer composed of 5 monomer units, each of L, 1 -!? is independently selected from the group consisting of hydrogen, hydroxy, nucleosides, naturally occurring nucleic acids, non-naturally occurring nucleic acids, aromatic moieties, DNA intercalators, nucleic acid-binding groups, heterocyclic moieties, and reporter ligands; each A 1 -A n is independently selected from the group consisting of (C 1 -C 4 )alkanoyl, and (C 1 -C 4 )thioalkanoyl; each of C x -C n is (CR ⁇ J y where R 1 is hydrogen and R 2 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R 1 and R 2 are independently selected from the group consisting of hydrogen, (C 2 -C 6 )alkyl, aryl, aralkyl, heteroaryl, hydroxy, (Ci-C alkoxy
  • each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10; each of G ⁇ G" '1 is CONR 3 , CSNR 3 , SONR 3 , S0 2 NR 3 , NR 3 CO,
  • Q is C0 2 H, CONR'R", S0 3 H or S0 2 NR'R" or an activated derivative of C0 2 H or S0 3 H;
  • I is NHR'"R"" or NR"'C(0)R"", where R' , R", R' ' ' and R' ' ' ' are independently selected from the group consisting of hydrogen, alkyl, amino protecting groups, reporter ligands, intercalators, chelators, amino acids, peptides, proteins, carbohydrates, lipids, steroids, nucleosides, nucleotides, nucleotide diphosphates, nucleotide triphosphates, oligonucleotides, oligonucleosides and soluble and non-soluble polymers.
  • R' , R", R' ' ' and R' ' ' ' are oligonucleotides or oligonucleosides
  • such structures can be considered chimeric structures between PNA compounds and the oligonucleotide or oligonucleoside.
  • ligands at either terminus (Q or I) to modulate the binding characteristics of the oligomers.
  • Representative examples include DNA intercalators which improve dsDNA binding, or basic groups, such as lysine, which strengthen binding of the oligomers due to electrostatic interaction.
  • charged groups such as carboxyl and sulfo groups could be used.
  • PNA oligomers useful for binding to and forming triple helical structures with DNA are compounds of the formula:
  • R 1 is H, C0CH 3 or COGly.
  • PNA oligomers form triple helices with dsDNA, and the resulting triplexes, i . e . (PNA) 2 /DNA, are significantly more stable than the corresponding DNA triplexes. While not wishing to be bound by theory, it is believed that a first strand of PNA oligomer binds to dsDNA, and in doing so displaces one strand of the dsDNA. Subsequent to this first binding event, a second strand of PNA oligomer binds to the resultant PNA/DNA structure forming a triple helix. In binding with DNA, PNA oligomers utilize Watson-Crick and Hoogsteen hydrogen bonding. PNA oligomers may also utilize reversed Hoogsteen hydrogen bonding. Furthermore, PNA oligomers bind to DNA in either a parallel or anti-parallel orientation.
  • PNA oligomers having about 5 monomer units may bind to DNA.
  • a preferred oligomer comprises at least 5 to about 60 monomer units. Sequences between 10 and 20 monomer units are of particular interest since this is the average length (in nucleotide units) of unique DNA sequences in prokaryotes and eukaryotes. Sequences of 15-18 monomer units are of special interest since this is the average length (in nucleotide units) of unique DNA sequences in the human genome.
  • NFKB is a transcription factor that is involved in the regulation of a set of genes encoding immunoreceptors, cytokines and viral proteins. It has been determined that NFKB is a heterodimer consisting of two distinct subunits with molecular masses of 50 kD (p50) and 65 kD (p65) . [Cell 1986, 46, 705; Genes and Development 1989, 3, 1689] .
  • NFKB regulates the expression of proteins such as ⁇ -IFN, MHC- class II, IL-6, HLA, TNF- ⁇ , lymphotoxin, and several viral promoters such as the HIV-1 enhancer. [Nature 1987, 330, 391.]
  • the consensus binding site for ⁇ FKB is the decamer GGGGACTTTCC. It is known that that there is no homology between sequences flanking this consensus sequence and that there is some degeneracy among the five most 3' nucleotides of the consensus sequence. Thus, by taking advantage of the sequence differences at the 3' end of the consensus sequence and the contiguous flanking sequences, oligomers can be designed which are specific for individual ⁇ FKB binding sites on specific promoters. Inhibition of the binding of ⁇ FKB to its binding site on the promoter results in inhibition of transcriptional activation and hence inhibition of protein production.
  • IL-2R ⁇ interleukin-2 ⁇ receptor
  • IL-2R ⁇ interleukin-2 ⁇ receptor
  • the IL-2R ⁇ promoter contains an ⁇ FKB binding site, the 3' end of which is overlapped by a 15 base homopyrimidine stretch.
  • a preferred embodiment of the present invention proposes use of a P ⁇ A oligomer specific for the 3' region of IL-2R ⁇ and its flanking sequences, which would not be predicted to be capable of binding to NFKB binding sites on other promoters. Oligomers that inhibit NFcB-mediated expression of the interleukin-2 ⁇ receptor may serve as effective therapeutics for disease conditions associated with inflammation.
  • oligomers which are specific for those gene promoters, preferably those comprising a homopyrimidine tract, may be useful in modulating gene expression.
  • HIV human immunodeficiency virus
  • NFKB contributes to growth of certain cancers such as melanoma, colon carcinoma, osteosarcoma and breast carcinoma.
  • Inhibition of the function of NFKB may therefore provide novel therapeutic approaches for these disease states.
  • Atherosclerosis is a vascular disorder associated with high morbidity, which is characterized by the presence of atherosclerotic lesions. It is a disorder of muscular arteries, such as the carotid and coronary arteries and arteries of the lower extremities. Elastic arteries, such as the aorta and iliac vessels, may also be affected. Atherosclerotic lesions occlude the arterial lumen which leads to additional complications including thrombosis, hemorrhage, embolism and dissection.
  • NFKB plays a role in the development of neurodegenerative diseases such as Down's Syndrome, Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease.
  • intrathecal or intraventricular administration of oligomers may be preferable.
  • oligomers of the invention For use as therapeutics, it may be desirable to target oligomers of the invention to specific cells of the body. Toward this end, it may be of interest to conjugate the oligomers of the invention with low molecular weight ligands such as folic acid, cholesterol and fatty acids.
  • the oligomers may also be conjugated to proteins such as enzymes and antibodies, oligonucleotides, carbohydrates, liposomes (such as cationic lipids) or intercalators in order that they may be targeted to the specific cell types in which it is desirable to effect inhibition of gene expression.
  • proteins such as enzymes and antibodies, oligonucleotides, carbohydrates, liposomes (such as cationic lipids) or intercalators in order that they may be targeted to the specific cell types in which it is desirable to effect inhibition of gene expression.
  • Other transcription factors such as fos, jun, SRF,
  • NF-IL6, Jun/AP-1, STAT-91, NF-jun, EGR-1 and HIVEN86A have also been implicated in a number of disease states. [Cell 1988, 53 , 827; TiPS 1994, 15, 239; Blood 1994, 84 , 1950; J. Biol . Chem. 1994, 269, 21682; Mol . Cell . Biol . 1994, 14 , 4759;] It is believed that inhibiting transcription factor binding to promoter sequences, preferably those comprising homopyrimidine segments, is useful in modulating aberrant or abnormal gene expression and thus in diagnosing and treating diseases.
  • Oligomers of the invention may also be used as adjuvant therapeutics in combination with other traditional therapeutic modalities for the alleviation of symptoms associated with a disease or for ablation of the disease.
  • the oligomers may be used in conjunction with AZT for the treatment of AIDS, or with sulfasalazine for the treatment of ulcerative colitis and Crohn's disease.
  • the oligomers may also be used as adjuvants with tamoxifen for the treatment of breast cancer, with 5-fluorouracil for the treatment of colon cancer, with pentoxifylline for the treatment of atherosclerosis, or with carbidopa for the management of Parkinson's disease.
  • oligomers such as peptide nucleic acids (PNAs) bind to dsDNA and form stable triple helical complexes.
  • PNAs peptide nucleic acids
  • Strand invasion of D ⁇ A by a P ⁇ A oligomer is a more efficient method of inhibiting the binding of a transcription factor, such as ⁇ F/cB, than prior reagents such as oligonucleotides.
  • Complexes between homopyrimidine P ⁇ A oligomers and complementary D ⁇ A exhibit 2:1 stoichiometry, i.e., two P ⁇ A oligomers bind to a complementary D ⁇ A strand. This stoichiometry has been demonstrated by gel mobility assay and electrospray mass spectrometry.
  • P ⁇ A oligomers are superior to prior reagents such as oligonucleotides in that they have significantly higher affinity for complementary D ⁇ A as demonstrated by their thermal melt temperatures (TJ . [Science 1991, 254 , 1497; J. Am . Chem . Soc . 1992, 114 , 1895; J " . Am. Chem . Soc . 1992, 114 , 9677.]
  • TJ thermal melt temperatures
  • the T m for a P ⁇ A/D ⁇ A complex is about two-fold higher than the T m for a corresponding D ⁇ A/D ⁇ A complex.
  • the triple helix formed between two homopyrimidine P ⁇ A oligomers and a complementary homopurine D ⁇ A strand is stable under physiological conditions for a longer period of time than is an oligonucleotide-dsD ⁇ A triplex.
  • a charged species such as a lysine moiety may be added
  • P ⁇ A oligomers possess no charge are water-soluble, and contain amides of non-biological amino acids.
  • PNA oligomers cause strand displacement and form triplex structures with DNA.
  • the invention described herein demonstrates specific inhibition of NFKB binding and transactivation by a PNA oligomer targeted to the IL-2R ⁇ promoter.
  • PNA oligomers bind to duplex DNA with sufficient affinity to prevent the binding of p50 (one subunit of NF/cB) to DNA. Binding of a PNA oligomer to a duplex DNA target correlates with inhibition of transcription factor (NF/cB) binding.
  • binding of a transcription factor to the IL-2R ⁇ gene is inhibited.
  • strand invasion by a PNA oligomer is used to inhibit transcriptional activation by NFKB.
  • strand invasion by a PNA oligomer results in disruption of the binding of p50 (one subunit of NFKB) to DNA.
  • Strand invasion of duplex DNA by a PNA oligomer specifically inhibits NF ⁇ B-mediated transcriptional activation in an eukaryotic nuclear lysate. It has been found, according to the present invention, that the PNA/DNA/PNA triplexes are stable up to 24 hours after formation in cell culture, and are capable of inhibiting transcriptional activation in cells.
  • the oligomers of the invention are useful as research reagents for the determination of transcription factor binding sites on DNA. They may also be used for the comparison of other compounds that are being evaluated for their activity as inhibitors of transcription factor binding to DNA.
  • the oligomers of the present invention are also suitable for ' use as diagnostic agents to confirm the involvement of a particular transcription factor in a given disease state.
  • Transcriptional activation mediated by the transcription factor leads to expression of a protein that is responsible for initiating and maintaining the disease state.
  • a number of assays employing the present invention may be formulated, which assays will commonly comprise quantitation of the protein expressed as a result of transcriptional activation mediated by a transcription factor suspected of involvement in the disease state, in a cell suspension, a tissue sample or a sample of a bodily fluid from a patient having said disease state.
  • Oligomers such as oligonucleotides are accepted as therapeutic moieties in the treatment of disease states such as cancer, AIDS and other viral diseases.
  • disease states such as cancer, AIDS and other viral diseases.
  • oligomers of the invention may be successfully used for the treatment of certain disease states.
  • a disease condition arising from transcription factor-dependent transcriptional activation are provided.
  • the formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art.
  • a patient in need of such therapy is administered an oligomer in accordance with the invention, commonly in a pharmaceutically acceptable carrier, in doses ranging from 0.01 ⁇ g to 100 g per kg of body weight depending on the age of the patient and the severity of the disease state being treated.
  • the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease, its severity and the overall condition of the patient, and may extend from once or more daily to once every 20 years.
  • the dosage of the oligomer may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disease state is observed or if the disease state has been ablated.
  • a patient being treated for AIDS may be administered an oligomer in conjunction with AZT, or a patient with atherosclerosis may be treated with an oligomer of the invention following angioplasty to prevent reocclusion of the treated arteries.
  • compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal) , oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.
  • Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • Coated condoms, gloves and the like may also be useful.
  • compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.
  • compositions for intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
  • Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
  • Dosing is dependent on severity and responsiveness of the disease condition to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of disease state is achieved.
  • Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates.
  • Optimum dosages may vary depending on the relative potency of individual oligomers, and can generally be estimated based on EC 50 s found to be effective in in vi tro and in vivo animal models. In general, dosage is from 0.01 ⁇ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years.
  • oligomer shall mean a compound comprising a plurality of monomer units including, but not limited to, nucleosides, naturally occurring nucleic acids, non-naturally occurring nucleic acids, aromatic moieties, DNA intercalators, nucleic acid-binding groups and heterocyclic moieties, connected via covalent linkages including, but not limited to, amides, thioamides, sulfonamides and sulfinamides.
  • homopyrimidine shall mean that substantially all monomer units are pyrimidine bases. Further, the term “homopurine” shall mean that substantially all monomer units are purine bases.
  • strand invasion or “strand displacement” shall mean displacement of one strand of dsDNA caused by the binding of one or more oligomers to the other strand of dsDNA.
  • modulation as it refers to gene expression shall mean inhibition or stimulation. Inhibition is presently the preferred form of modulation.
  • parallel orientation shall mean that the amino terminus of the PNA oligomer (bearing a glycine residue in oligomers of SEQ. ID NOS.
  • oligomers of the invention are complementary to the 5' end of DNA, and the carboxy terminus of the PNA oligomer (bearing a lysine residue in oligomers of SEQ. ID NOS. 3 and 4) is complementary to the 3' end of DNA.
  • anti- parallel orientation shall mean that the amino terminus of the PNA oligomer is complementary to the 3' end of DNA.
  • transcriptional activation shall mean the initiation of transcription following the binding of a transcription factor to its binding site on DNA.
  • duplex DNA shall mean double-stranded DNA (dsDNA) .
  • tissue, cells or bodily fluids are contacted with oligomers of the invention.
  • contacting tissues, cells or a bodily fluid with an oligomer is meant to add the oligomer, usually in a liquid carrier, to a cell suspension, tissue sample or a sample of a bodily fluid, either in vi tro or ex vivo, or to administer the oligomer to cells, tissues or bodily fluids in vivo to an animal.
  • hybridization shall mean hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary monomer units.
  • adenine and thymine are complementary bases which pair through the formation of hydrogen bonds.
  • “Complementary,” as used herein, also refers to subunit sequence complementarity between two monomer units. For example, if a monomer unit at a certain position of an oligomer is capable of hydrogen bonding with a base at the same position of a DNA molecule, then the oligomer and DNA are considered to be complementary to each other at this position.
  • the oligomer molecule and the DNA molecule are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by monomer units or bases which can hydrogen bond with each other.
  • “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA target and the oligomer. It is understood that an oligomer need not be 100% complementary to its target DNA sequence to be specifically hybridizable.
  • An oligomer is specifically hybridizable when binding of the oligomer to the target DNA molecule interferes with the normal function of the target DNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligomer to non-target sequences under conditions in which specific binding is desired, i . e . , under physiological conditions in the case of in vivo assays or therapeutic treatment, or in the case of in vi tro assays, under conditions in which the assays are performed.
  • PNAs were synthesized and purified according to the method of Egholm et al . (J. Am. Chem. Soc . 1992, 114 , 1895) and Sheppard ⁇ TIBTECH 1993, 11 , 492) .
  • DNA oligonucleotides were synthesized on an automated DNA synthesizer (Applied Biosystems model 38OB) using standard phosphoramidite chemistry with oxidation by iodine.
  • duplex DNA targets Two DNA targets, ISIS 9663 and ISIS 8134, were synthesized. The sequences of these oligonucleotides are shown in Table 1.
  • ISIS 9663 contains the IL-2R ⁇ NF/cB site and the PNA oligomer binding site (-247 to -267, according to the numbering of Cross et al . , Cell 1987, 49, 47) , flanked by universal primer sequences.
  • the NF/cB site and the homopyrimidine stretch are shown in boldface.
  • ISIS 8134 contains only the strand invasion site (shown in boldface) , with the NFcB site being deleted.
  • PNA affinity and NF/cB binding were produced by PCR amplification of each oligonucleotide using 32 P end labelled universal primers. After 30 rounds of PCR amplification, the full length duplex targets were purified by native polyacrylamide gel electrophoresis, followed by resuspension in the assay buffer. TABLE 1
  • PNA strand invasion Binding of PNA and NFcB to duplex DNA target was measured by gel mobility shift assay according to the procedure of Vickers and Ecker. [Nucleic Acids Research 1992, 20, 3945.]
  • radiolabeled DNA target about 10 pM was incubated with increasing concentrations of PNA in either TMTB (100 mM sodium, 10 mM phosphate, 0.1 mM EDTA) or TE (10 mM Tris, 0.1 mM EDTA, pH 7) . Following incubation, the PNA-bound DNA duplex was separated from the free target DNA duplex by electrophoresis using an 8% native polyacrylamide gel.
  • Two 15-base homopyrimidine PNAs ISIS 8129 and ISIS 9151, were designed to bind the homopurine strand of the target duplex DNA which overlaps the 3' end of the NFcB binding site of the IL-2R ⁇ promoter ( Figure 1) .
  • the sequences of these PNAs are shown in Table 2.
  • ISIS 8129 was fashioned to bind the target in an antiparallel orientation, while ISIS 9151 bound the target in a parallel orientation.
  • the EC 50 for strand invasion by each of the PNAs was measured in 100 mM sodium buffer (TMTB) by gel shift, and was defined as the concentration of PNA at which half of the target DNA was bound. Strand invasion rates were determined to be slow in TMTB. At 10 ⁇ M PNA, binding of ISIS 9151 to the target, ISIS 8134, did not begin to plateau until 5 days at 37°C.
  • the EC 50 after a 2 day incubation at 37°C, was determined to be 3.8 ⁇ M, while ISIS 8129 showed little affinity for the same target even at concentrations as high as 40 ⁇ M.
  • SI nuclease mapping of PNA-bound target DNA revealed that the homopyrimidine strand of the target DNA was displaced, and the DNA strands flanking the PNA binding site remained double-stranded.
  • Example 4 Determination of the effect of strand invasion on the binding of NF/cB to a duplex DNA target: ISIS 9151 (PNA) was preincubated with DNA duplex ISIS 9663 or DNA duplex ISIS 8134, both being generated by PCR. Preincubations were performed in Tris EDTA (TE, instead of TMTB) due to slow kinetics of strand invasion in high salt buffer.
  • TSB buffer Promega, 10 mM HEPES, pH 7.9, 50 mM KC1, 0.2 mM EDTA, 2.5 mM DTT, 10% glycerol, 0.05% NP40
  • 200 ng of purified NF/cB p50 was added.
  • the amount of p50 that bound in the presence of increasing concentrations of PNA was visualized by gel shift analysis. The results are shown in Figure 2.
  • the EC 50 for strand invasion of the duplex target was approximately 700 nM ( Figure 2, lanes 1-6) .
  • Length-matched control PNAs ISIS 11204 and ISIS 8130 (shown in Table 3) , did not bind to the target even at 10 ⁇ M, which was the highest concentration evaluated ( Figure 2, lanes 7 and 8) .
  • Purified p50 specifically bound to the target in the absence of PNA, presumably as a homodimer ( Figure 2, lane 11) .
  • this target was completely bound by PNA at a concentration of 10 ⁇ M of ISIS 9151 ( Figure 2, lanes 10 and 20) .
  • Plasmid construction Two oligonucleotides with SEQ. ID NO. 7 and SEQ. ID NO. 8 were annealed in PBS. The sequences of these two oligonucleotides are shown in Table 4. The resulting duplex contained tandem repeats of the NF/cB binding site and the homopyrimidine stretch (-247 to -267, according to the numbering of Cross et al . , Cell 1987, 49, 47) of the IL-2Rc ⁇ promoter, and Kpnl and Xhol sticky ends.
  • the duplex was ligated into the luciferase reporter vector pGL2-Promoter (Promega) at the same restriction sites, placing the NFcB binding site of IL-2R ⁇ just upstream of the SV40 promoter driving the expression of luciferase. SV40 enhancer sequences are not present in this vector.
  • the resulting plasmid was designated pGL-/cB.
  • the amount of full length (870 nucleotides) run-off transcript was increased by approximately 2-fold in the presence of NFcB p50 protein (lanes 1 and 2) .
  • the PNA ISIS 9151 inhibited the transactivation completely at 3.3 ⁇ M and 1 ⁇ M (lanes 3 and 6) .
  • the random mixed sequence PNA ISIS 8130 showed some inhibition of transactivation (lane 5) .
  • this non-specific inhibition was not observed at a PNA (ISIS 8130) concentration of 1 ⁇ M (lane 8) , or for the random homopyrimidine control PNA, ISIS 11204 (lanes 4 and 7) .
  • Cell culture HL 2/3 cells were maintained in DMEM with 10% fetal calf serum. For activity in cell culture, 3 ⁇ g of plasmid was incubated overnight with PNA in 30 ⁇ L TE. The following morning, 10 ⁇ L of the plasmid/PNA was digested for 30 minutes with 5 units each of EcoRl and Xhol . Restriction protection of the Xhol site by the invaded PNA was visualized by electrophoresis through a 1% agarose gel and ethidium bromide staining. The remaining 20 ⁇ L of the plasmid/PNA was brought to a volume of 100 ⁇ L with OptiMEM medium.
  • OptiMEM OptiMEM containing 10 ⁇ g of LipofectAmine (Gibco-BRL) , and incubated for 20 minutes at room temperature. This mixture was then divided between duplicate wells of 1 6-well plate containing 50% confluent HL 2/3 cells in 800 ⁇ L of OptiMEM. Following a 6- hour incubation at 37°C, the medium was removed and replaced with fresh DMEM containing 10% fetal calf serum. Immediately following the transfection, PMA (50 ng/mL) and PHA (0.5 ⁇ g/mL) were added to the cells to induce production of NF/cB. The cells were incubated overnight at 37°C. The following day, cells were harvested and assayed for luciferase activity.
  • PMA 50 ng/mL
  • PHA 0.5 ⁇ g/mL
  • NFcB was induced by the addition of PMA/PHA.
  • the cells were then incubated overnight and luciferase activity was measured the following day. The results are shown in Figure 4, and are expressed as the luciferase activity in light units relative to the uninduced controls.
  • ISIS 9151 inhibited transactivation of pGL-/cB completely, while the control PNAs had little effect. None of the PNAs had any effect on the transactivation of the control construct pGL2-C.
  • PNA concentrations of less than 1 ⁇ M very little inhibition of transactivation was observed, while at concentrations higher than 10 ⁇ M, inhibition was non-specific. It is noteworthy that once bound, the PNA/DNA/PNA triplex was sufficiently stable to produce an effect even after 24 hours in cell culture.
  • This Western blot assay involves detection and quantitation of a selected protein involved in a disease state, which protein is produced as a result of gene expression mediated by a given transcription factor.
  • a first sample of cells, tissues or a bodily fluid from a patient suspected of having the disease state is lysed in lysis buffer, electrophoresed on SDS-polyacrylamide gel, and transferred to a nitrocellulose filter according to standard methods [Molecular Cloning. A Laboratory Manual , 1989, Volume 3, Cold Spring Harbor Laboratory Press, NY, p. 18.60] .
  • the filter is subsequently exposed to an antibody which is specific for the selected protein to be detected and autoradiographed according to standard procedure.
  • a second identical sample of cells, tissues or a bodily fluid is incubated with an oligomer of the invention, washed to remove any unbound oligomer and lysed in lysis buffer.
  • the sample is then electrophoresed on SDS- polyacrylamide gel and transferred to a nitrocellulose filter according to standard methods.
  • the filter is subsequently exposed to an antibody and autoradiographed as above.
  • the intensity of the selected protein bands on the two autoradiograms are then compared. Absence of the protein band, or presence of the appropriate protein band having decreased intensity in the second sample, as contrasted with that in the first sample is an indication that the transcription factor which is detected is responsible for initiating the disease state.
  • the oligomers of the invention may be used for treatment of disease states arising due to transcriptional activation mediated by transcription factors.
  • Disease states that may be treated by administering oligomers of the invention include, but are not limited to, inflammatory disorders, AIDS, atherosclerosis and neurodegenerative diseases such as Down's Syndrome, Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease.
  • Treatment of a patient diagnosed with a particular disease state comprises administration of an effective dose of the oligomer, in a pharmaceutically accepted formulation, to the patient via an appropriate route.
  • the effective oligomer dose depends on the disease state being treated, the severity of the disease state and the age of the patient being treated.
  • the effective dose of an oligomer may be determined based on its IC 50 and is a routine procedure for one of skill in the art.
  • the effective dose of the oligomer may be determined by using the pharmacokinetics software program TopFit.
  • dosage of oligomers may vary from 0.01 ⁇ g to 100 g per kg of body weight depending on progression of the disease state.
  • the frequency of dosing depends on the progression of the disease state and may vary from once or more daily to once every 20 years.
  • the route of oligomer administration depends on the disease state being treated.
  • administration of an oligomer to a patient being treated for an inflammatory disorder such as ulcerative colitis may be accomplished either via oral or rectal routes.
  • the most effective method of oligomer administration may be an oral route or by subcutaneous injection.
  • Cancers such as breast cancer may be treated via subcutaneous injection, while colon cancer may be treated via oral or rectal administration of the oligomer.
  • a disease state such as atherosclerosis may best be treated by oral administration or subcutaneous injection.
  • treatment with the oligomer may be more effective if administered following angioplasty, thereby preventing reocclusion of the treated arteries of the patient.
  • a patient having a neurodegenerative disease such as Down's Syndrome, Alzheimer's disease, amyotrophic lateral sclerosis or Parkinson's disease may best be treated by intrathecal or intraventricular administration for delivery of the oligomer to the spinal column or the brain of the patient.
  • the patient may be monitored for alleviation of symptoms associated with the disease state. Subsequently, the dosage may be adjusted (increased or decreased) depending upon the severity and amenability of the disease state to treatment.
  • oligomers of the invention may be administered in combination with other traditional therapeutics.
  • the oligomers may be administered in combination with drugs including, but not limited to, AZT for the treatment of patients afflicted with AIDS, sulfasalazine for the treatment of an inflammatory disorder such as ulcerative colitis, and 5-fluorouracil for the treatment of colon cancer.
  • the dosage and frequency of oligomer administration as part of a maintenance regimen may vary from 0.01 ⁇ g to 100 g per kg of body weight, ranging from once or more daily to once every 20 years.
  • Intraventricular administration of oligomers may be desired for the treatment of patients with certain neurodegenerative disease.
  • a silicon catheter is surgically introduced into a ventricle of the brain of a human patient, and is connected to a subcutaneous infusion pump (Medtronic Inc., Minneapolis, MN) that has been surgically implanted in the abdominal region.
  • Medtronic Inc. Medtronic Inc., Minneapolis, MN
  • the pump is used to inject the oligomers and allows precise dosage adjustments and variation in dosage schedules with the aid of an external programming device.
  • the reservoir capacity of the pump is 18-20 mL and infusion rates may range from 0.1 mL/h to 1 mL/h.
  • the pump reservoir may be refilled at 3-10 week intervals. Refilling of the pump is accomplished by percutaneous puncture of the self-sealing septum of the pump.
  • Intrathecal administration of oligomers Intrathecal drug administration for the introduction of drug into the spinal column of a patient may be desired for the treatment of patients with certain neurodegenerative diseases.
  • a silicon catheter is surgically implanted into the L3-4 lumbar spinal interspace of a human patient, and is connected to a subcutaneous infusion pump which has been surgically implanted in the upper abdominal region.
  • the reservoir capacity of the pump is 18-20 mL, and infusion rates may vary from 0.1 mL/h to 1 mL/h.
  • infusion rates may vary from 0.1 mL/h to 1 mL/h.
  • dosage of drug to be administered ranging from 0.01 ⁇ g to 100 g per kg of body weight
  • the pump reservoir may be refilled at 3-10 week intervals. Refilling of the pump is accomplished by a single percutaneous puncture to the self-sealing septum of the pump.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des compositions et des procédés qui permettent d'inhiber l'expression génique dans des systèmes biologiques, et ce grâce à l'inhibition de la liaison des facteurs de transcription à l'ADN. On parvient à cette inhibition de la liaison des facteurs de transcription à l'ADN, dans les modes de réalisation préférés de l'invention à l'aide d'oligomères complémentaires de l'ADN cible. De préférence, ces oligomères sont des oligomères d'acides nucléiques de peptides (PNA). Cette invention concerne également des compositions utiles en tant qu'inhibiteurs de l'expression génique.
PCT/US1996/006673 1995-05-10 1996-05-10 Inhibition, au moyen d'une invasion de brins oligomeres, de l'activation par transcription induite par un facteur de transcription WO1996035705A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58565/96A AU5856596A (en) 1995-05-10 1996-05-10 Inhibition of transcription factor-mediated transcriptional activation by oligomer strand invasion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43837995A 1995-05-10 1995-05-10
US08/438,379 1995-05-10

Publications (1)

Publication Number Publication Date
WO1996035705A1 true WO1996035705A1 (fr) 1996-11-14

Family

ID=23740427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/006673 WO1996035705A1 (fr) 1995-05-10 1996-05-10 Inhibition, au moyen d'une invasion de brins oligomeres, de l'activation par transcription induite par un facteur de transcription

Country Status (2)

Country Link
AU (1) AU5856596A (fr)
WO (1) WO1996035705A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033867A3 (fr) * 1997-12-23 1999-09-02 Roche Diagnostics Gmbh Analogues d'acide nucleique modifies
US6472209B1 (en) 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6723560B2 (en) 1998-10-08 2004-04-20 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
EP1042349A4 (fr) * 1997-10-17 2004-07-28 Mayo Foundation For Medicaledu Utilisation d'oligomeres d'acides nucleiques de polyamide pour declencher une reaction biologique

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEM., February 1994, Vol. 5, NIELSEN et al., "Peptide Nucleic Acid (PNA): A DNA Mimic with a Peptide Backbone", pages 3-7. *
J. AM. CHEM. SOC., 18 January 1995, Vol. 117, GRIFFITH et al., "Single and Bis Peptide Nucleic Acids as Triplexing Agents: Binding and Stoiciometry", pages 831-832. *
J. BIOL. CHEM., 15 February 1992, Vol. 267, GRIGORIEV et al., "A Triple Helix-Forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor Via Inhibition of NF kB Binding to Interleukin-2 Receptor A-Regulatory Sequence", pages 3389-3395. *
NATURE, 07 October 1993, Vol. 365, EGHOLM et al., "PNA Hybridizes to Complementary Oligonucleotides Obeying the Watson-Crick Hydrogen-Bonding Rules", pages 566-568. *
NIELSEN et al., "Antisense Research and Applications", ANN. ARBOR: CRC PRESS, 1993, pages 363-373. *
NUCLEIC ACIDS RES., 11 August 1995, Vol. 23, VICKERS et al., "Inhibition of NF-kB Specific Transcriptional Activation by PNA Strand Invasion", pages 3003-3008. *
PERSEPTIVE BIOSYSTEMS 'ENABLING TECHNOLOGIES' BULLETIN, 1995, "Expedite PNA Synthesis Products", pages 1-4. *
PROC. NATL. ACAD. SCI. U.S.A., November 1993, HIGGINS et al., "Antisense Inhibition of the p65 Subunit of NF-kB Blocks Tumorigenicity and Causes Tumor Regression", pages 9901-9905. *
PROC. NATL. ACAD. SCI. U.S.A., November 1993, Vol. 90, PEFFER et al., "Strand-Invasion of Duplex DNA by Peptide Nucleic Acid Oligomers", pages 10648-10652. *
SCIENCE, 11 December 1992, Vol. 258, KITAJIMA et al., "Ablation of HTLV-1 Tax-Transformed Tumors in Mice by Antisense Inhibition of NF-kB", pages 1792-1795. *
SCIENCE, August 1989, Vol. 245, MAHER et al., "Inhibition of DNA-Binding Proteins by Oligonucleotide-Directed Triple Helix Formation", pages 725-730. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472209B1 (en) 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6743627B1 (en) 1997-10-17 2004-06-01 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
EP1042349A4 (fr) * 1997-10-17 2004-07-28 Mayo Foundation For Medicaledu Utilisation d'oligomeres d'acides nucleiques de polyamide pour declencher une reaction biologique
US6989270B1 (en) 1997-10-17 2006-01-24 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
WO1999033867A3 (fr) * 1997-12-23 1999-09-02 Roche Diagnostics Gmbh Analogues d'acide nucleique modifies
US6723560B2 (en) 1998-10-08 2004-04-20 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response

Also Published As

Publication number Publication date
AU5856596A (en) 1996-11-29

Similar Documents

Publication Publication Date Title
US5986053A (en) Peptide nucleic acids complexes of two peptide nucleic acid strands and one nucleic acid strand
Uhlmann et al. PNA: synthetic polyamide nucleic acids with unusual binding properties
JP2937481B2 (ja) 多薬剤耐性関連タンパク質のオリゴヌクレオチド調整
JP3121599B2 (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
AU698739B2 (en) Oligonucleotides having phosphorothioate linkages of high chiral purity
US5849900A (en) Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids
US6380169B1 (en) Metal complex containing oligonucleoside cleavage compounds and therapies
US20030207804A1 (en) Modified peptide nucleic acids
US6734161B1 (en) Peptide nucleic acids having antibacterial activity
WO1994007367A9 (fr) Oligomeres antiviraux liant des voies de polypurine d'arn monocatenaire ou d'hybrides d'arn-adn
EP4083208A1 (fr) Acide nucléique antisens qui induit le saut de l'exon 50
WO1998034945A1 (fr) Modification ciblee du gene ccr-5
US5856099A (en) Antisense compositions and methods for modulating type I interleukin-1 receptor expression
WO1996035705A1 (fr) Inhibition, au moyen d'une invasion de brins oligomeres, de l'activation par transcription induite par un facteur de transcription
McMahon et al. Peptide nucleic acids specifically cause antigene effects in vivo by systemic injection
McMahon et al. Intraperitoneal injection of antisense peptide nucleic acids targeted to the mu receptor decreases response to morphine and receptor protein levels in rat brain
WO1996040157A1 (fr) UTILISATION D'OLIGONUCLEOTIDES ANTISENS COMPLEMENTAIRES DE L'ARNm DU RECEPTEUR DE L'INTERLEUKINE-6 POUR INHIBER LA PROLIFERATION CELLULAIRE
AU684774B2 (en) Formation of triple helix complexes using a novel motif
US5945336A (en) Oligonucleotides and methods for inhibiting cellular proliferation
US20050048552A1 (en) Higher order structure and binding of peptide nucleic acids
WO1995003833A1 (fr) Oligomeres modulant la proteine kinase c
KR100257972B1 (ko) 높은 키랄 순도의 포스포로티오에이트 결합기를 가지는 올리고뉴클레오티드
HK40081034A (en) Antisense nucleic acid that induces skipping of exon 50
Beck et al. 3 Peptide Nucleic Acid (PNA): A
BRADLEY et al. International Conference on Nucleic Acid Medical Applications, NAMA Conference

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase